


MEDICINAL PRODUCTS 2023

**ARCA

ARCA biopharma Inc. Rank 8 of 48





MEDICINAL PRODUCTS 2023



ARCA biopharma Inc. Rank 8 of 48

The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 147% points. The greatest weakness of ARCA biopharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 120% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	42,699
Assets, Non-Current	361
General and Administrative Expense	5,847
Goodwill	0
Liabilities, Current	1,132
Liabilities, Non-Current	280
Other Assets	0
Other Compr. Net Income	0
Other Expenses	5.0
Other Liabilities	0
Other Net Income	0
Other Revenues	675
Property, Plant and Equipment, Net	25
Research and Development	4,749

Output Variable	Value in 1000 USD
Liabilities	1,412
Assets	43,085
Expenses	10,601
Revenues	675
Stockholders Equity	41,673
Net Income	-9,926
Comprehensive Net Income	-9,926
Economic Capital Ratio	115%

